Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 11
---
 “Recent Developments—November
2025 Registered Direct Offering” below for additional information), and as of November 14, 2025, we issued 2,090,987 common shares
as a result of the exercises for cash and on a cashless basis of warrants to purchase 2,894,769 common shares, which were previously
classified as a liability given certain of their contractual terms which precluded equity classification, that were issued in our financings
in in April 2023 and January 2024 for aggregate gross proceeds of approximately $183,000 (see “Recent Developments—Warrant
Exercises” below for additional information). We expect that we will be able to demonstrate compliance with the Nasdaq stockholders’
equity requirement as a result of this offering and the aforementioned financing and warrant exercises.

November 2025 Registered Direct Offering

On November 13, 2025, we entered
into a definitive securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded
warrants to purchase up to 2,984,146 common shares, in a registered direct offering, or the November 2025 Offering, at a purchase price
of $0.20 per common share and $0.1999 per pre-funded warrant.

The pre-funded warrants are
immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire
until exercised in full.

The November 2025 Offering
closed on November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million.

<div align='center'>S-3</div>

Warrant Exercises

As of November 14, 2025, investors
from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants
to purchase 1,881,250 common shares on a cashless basis. As a result, we issued an aggregate of 2,090,987 common shares and received aggregate
gross proceeds of approximately $183,000 from such exercises.

Convertible Notes Securities Purchase Agreement

On September 17, 2025, we
entered into the SPAs with the CLA Investors. The SPAs provide that, upon the terms and subject to the conditions set forth therein, we
shall issue and sell to the CLA